A Phase I Study of E7050 in Subjects With Solid Tumors
The purpose of this study is to investigate the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally once daily to patients with advanced solid tumor and gastric cancer.
Solid Tumor|Gastric Cancer
DRUG: E7050
Determination of the maximum tolerated dose (MTD), Determination of the MTD of E7050 given orally once daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT)., During the Run-in Phase and Cycle 1 period (the first 5 weeks of treatment)
The purpose of this study is to investigate the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally once daily to patients with advanced solid tumor and gastric cancer.